ATXA Therapeutics is developing novel small molecule antagonists of the Thromboxane Receptor (TP) to treat Pulmonary Arterial Hypertension, a condition characterized by high blood pressure in the lungs that can lead to heart failure. Their lead candidate, NTP42, aims to address significant unmet clinical needs in cardiopulmonary disease management.
Funding
$14.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Pulmonary Arterial Hypertension (PAH) is characterized by elevated blood pressure in the pulmonary arteries, leading to right heart failure and limited treatment options. Current therapies often fail to adequately address the underlying disease mechanisms, leaving a significant unmet need for more effective treatments.
Solution
ATXA Therapeutics is developing small molecule Thromboxane Receptor (TP) antagonists, with a lead candidate NTP42, to treat PAH by targeting a key driver of disease progression in the heart and lungs. By blocking the TP receptor, NTP42 aims to reduce pulmonary artery pressure, improve right ventricular function, and ultimately enhance the quality of life for PAH patients. The therapeutic approach has the potential to address multiple cardiopulmonary diseases with high unmet clinical needs.
Target Audience
The primary target audience includes patients diagnosed with Pulmonary Arterial Hypertension (PAH) and the physicians (pulmonologists, cardiologists) who manage their care.
Features
- NTP42: A novel, small molecule antagonist of the Thromboxane Receptor (TP).
- Designed to selectively block TP receptor activation, reducing vasoconstriction and inflammation in the pulmonary arteries.
- Oral formulation for convenient administration.
- Potential for use as a monotherapy or in combination with existing PAH treatments.
- Clinical-stage development with Phase 1 safety and tolerability data available.